Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea

A multi-center, retrospective observational study

Sang Hoon Park, Choong Kee Park, Jin Woo Lee, Young Seok Kim, Sook Hyang Jeong, Yun Soo Kim, Ju Hyun Kim, Seong Gyu Hwang, Kyu Sung Rim, Hyung Joon Yim, Jae Youn Cheong, Sung Won Cho, June Sung Lee, Young Min Park, Jeong Won Jang, Chun Kyon Lee, Joo Hyun Shon, Jin Mo Yang, Young Soo Ju

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background/Aims: We aimed to evaluate the efficacy and safety of peginterferon plus ribavirin for chronic hepatitis C (CHC) patients under real life setting in Korea. Methods: We retrospectively analyzed the medical records of 758 CHC patients treated with peginterferon plus ribavirin between 2000 and 2008 from 14 university hospitals in the Gyeonggi- Incheon area in Korea. Results: Hepatitis C virus (HCV) genotype 1 was detected in 61.2% of patients, while genotype 2 was detected in 35.5%. Baseline HCV RNA level was ≥6×10 5 IU/mL in 51.6% of patients. The sustained virological response (SVR) rate was 59.6% regardless of genotype; 53.6% in genotype 1 and 71.4% in genotype 2/3. On multivariate analysis, male gender (p=0.011), early virological response (p<0.001), genotype 2/3 (p<0.001), HCV RNA <6×10 5 IU/ mL (p=0.005) and adherence to the drug >80% of the planned dose (p<0.001) were associated with SVR. The rate of premature discontinuation was 35.7%. The main reason for withdrawal was intolerance to the drug due to common adverse events or cytopenia (48.2%). Conclusions: Our data suggest that the efficacy of peginterferon and ribavirin therapy in Koreans is better in Koreans than in Caucasians for the treatment of CHC, corroborating previous studies that have shown the superior therapeutic efficacy of this regimen in Asians.

Original languageEnglish
Pages (from-to)98-106
Number of pages9
JournalGut and Liver
Volume6
Issue number1
DOIs
Publication statusPublished - 2012 Jan 1

Fingerprint

Ribavirin
Chronic Hepatitis C
Korea
Observational Studies
Retrospective Studies
Genotype
Hepacivirus
Therapeutics
Medical Records
Multivariate Analysis
RNA
Safety
Pharmaceutical Preparations

Keywords

  • Chronic hepatitis C
  • Korean
  • Pegylated interferon alpha
  • Ribavirin

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea : A multi-center, retrospective observational study. / Park, Sang Hoon; Park, Choong Kee; Lee, Jin Woo; Kim, Young Seok; Jeong, Sook Hyang; Kim, Yun Soo; Kim, Ju Hyun; Hwang, Seong Gyu; Rim, Kyu Sung; Yim, Hyung Joon; Cheong, Jae Youn; Cho, Sung Won; Lee, June Sung; Park, Young Min; Jang, Jeong Won; Lee, Chun Kyon; Shon, Joo Hyun; Yang, Jin Mo; Ju, Young Soo.

In: Gut and Liver, Vol. 6, No. 1, 01.01.2012, p. 98-106.

Research output: Contribution to journalArticle

Park, SH, Park, CK, Lee, JW, Kim, YS, Jeong, SH, Kim, YS, Kim, JH, Hwang, SG, Rim, KS, Yim, HJ, Cheong, JY, Cho, SW, Lee, JS, Park, YM, Jang, JW, Lee, CK, Shon, JH, Yang, JM & Ju, YS 2012, 'Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: A multi-center, retrospective observational study', Gut and Liver, vol. 6, no. 1, pp. 98-106. https://doi.org/10.5009/gnl.2012.6.1.98
Park, Sang Hoon ; Park, Choong Kee ; Lee, Jin Woo ; Kim, Young Seok ; Jeong, Sook Hyang ; Kim, Yun Soo ; Kim, Ju Hyun ; Hwang, Seong Gyu ; Rim, Kyu Sung ; Yim, Hyung Joon ; Cheong, Jae Youn ; Cho, Sung Won ; Lee, June Sung ; Park, Young Min ; Jang, Jeong Won ; Lee, Chun Kyon ; Shon, Joo Hyun ; Yang, Jin Mo ; Ju, Young Soo. / Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea : A multi-center, retrospective observational study. In: Gut and Liver. 2012 ; Vol. 6, No. 1. pp. 98-106.
@article{23a3a4519e7d4eebb33293330a0a7235,
title = "Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: A multi-center, retrospective observational study",
abstract = "Background/Aims: We aimed to evaluate the efficacy and safety of peginterferon plus ribavirin for chronic hepatitis C (CHC) patients under real life setting in Korea. Methods: We retrospectively analyzed the medical records of 758 CHC patients treated with peginterferon plus ribavirin between 2000 and 2008 from 14 university hospitals in the Gyeonggi- Incheon area in Korea. Results: Hepatitis C virus (HCV) genotype 1 was detected in 61.2{\%} of patients, while genotype 2 was detected in 35.5{\%}. Baseline HCV RNA level was ≥6×10 5 IU/mL in 51.6{\%} of patients. The sustained virological response (SVR) rate was 59.6{\%} regardless of genotype; 53.6{\%} in genotype 1 and 71.4{\%} in genotype 2/3. On multivariate analysis, male gender (p=0.011), early virological response (p<0.001), genotype 2/3 (p<0.001), HCV RNA <6×10 5 IU/ mL (p=0.005) and adherence to the drug >80{\%} of the planned dose (p<0.001) were associated with SVR. The rate of premature discontinuation was 35.7{\%}. The main reason for withdrawal was intolerance to the drug due to common adverse events or cytopenia (48.2{\%}). Conclusions: Our data suggest that the efficacy of peginterferon and ribavirin therapy in Koreans is better in Koreans than in Caucasians for the treatment of CHC, corroborating previous studies that have shown the superior therapeutic efficacy of this regimen in Asians.",
keywords = "Chronic hepatitis C, Korean, Pegylated interferon alpha, Ribavirin",
author = "Park, {Sang Hoon} and Park, {Choong Kee} and Lee, {Jin Woo} and Kim, {Young Seok} and Jeong, {Sook Hyang} and Kim, {Yun Soo} and Kim, {Ju Hyun} and Hwang, {Seong Gyu} and Rim, {Kyu Sung} and Yim, {Hyung Joon} and Cheong, {Jae Youn} and Cho, {Sung Won} and Lee, {June Sung} and Park, {Young Min} and Jang, {Jeong Won} and Lee, {Chun Kyon} and Shon, {Joo Hyun} and Yang, {Jin Mo} and Ju, {Young Soo}",
year = "2012",
month = "1",
day = "1",
doi = "10.5009/gnl.2012.6.1.98",
language = "English",
volume = "6",
pages = "98--106",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "1",

}

TY - JOUR

T1 - Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea

T2 - A multi-center, retrospective observational study

AU - Park, Sang Hoon

AU - Park, Choong Kee

AU - Lee, Jin Woo

AU - Kim, Young Seok

AU - Jeong, Sook Hyang

AU - Kim, Yun Soo

AU - Kim, Ju Hyun

AU - Hwang, Seong Gyu

AU - Rim, Kyu Sung

AU - Yim, Hyung Joon

AU - Cheong, Jae Youn

AU - Cho, Sung Won

AU - Lee, June Sung

AU - Park, Young Min

AU - Jang, Jeong Won

AU - Lee, Chun Kyon

AU - Shon, Joo Hyun

AU - Yang, Jin Mo

AU - Ju, Young Soo

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Background/Aims: We aimed to evaluate the efficacy and safety of peginterferon plus ribavirin for chronic hepatitis C (CHC) patients under real life setting in Korea. Methods: We retrospectively analyzed the medical records of 758 CHC patients treated with peginterferon plus ribavirin between 2000 and 2008 from 14 university hospitals in the Gyeonggi- Incheon area in Korea. Results: Hepatitis C virus (HCV) genotype 1 was detected in 61.2% of patients, while genotype 2 was detected in 35.5%. Baseline HCV RNA level was ≥6×10 5 IU/mL in 51.6% of patients. The sustained virological response (SVR) rate was 59.6% regardless of genotype; 53.6% in genotype 1 and 71.4% in genotype 2/3. On multivariate analysis, male gender (p=0.011), early virological response (p<0.001), genotype 2/3 (p<0.001), HCV RNA <6×10 5 IU/ mL (p=0.005) and adherence to the drug >80% of the planned dose (p<0.001) were associated with SVR. The rate of premature discontinuation was 35.7%. The main reason for withdrawal was intolerance to the drug due to common adverse events or cytopenia (48.2%). Conclusions: Our data suggest that the efficacy of peginterferon and ribavirin therapy in Koreans is better in Koreans than in Caucasians for the treatment of CHC, corroborating previous studies that have shown the superior therapeutic efficacy of this regimen in Asians.

AB - Background/Aims: We aimed to evaluate the efficacy and safety of peginterferon plus ribavirin for chronic hepatitis C (CHC) patients under real life setting in Korea. Methods: We retrospectively analyzed the medical records of 758 CHC patients treated with peginterferon plus ribavirin between 2000 and 2008 from 14 university hospitals in the Gyeonggi- Incheon area in Korea. Results: Hepatitis C virus (HCV) genotype 1 was detected in 61.2% of patients, while genotype 2 was detected in 35.5%. Baseline HCV RNA level was ≥6×10 5 IU/mL in 51.6% of patients. The sustained virological response (SVR) rate was 59.6% regardless of genotype; 53.6% in genotype 1 and 71.4% in genotype 2/3. On multivariate analysis, male gender (p=0.011), early virological response (p<0.001), genotype 2/3 (p<0.001), HCV RNA <6×10 5 IU/ mL (p=0.005) and adherence to the drug >80% of the planned dose (p<0.001) were associated with SVR. The rate of premature discontinuation was 35.7%. The main reason for withdrawal was intolerance to the drug due to common adverse events or cytopenia (48.2%). Conclusions: Our data suggest that the efficacy of peginterferon and ribavirin therapy in Koreans is better in Koreans than in Caucasians for the treatment of CHC, corroborating previous studies that have shown the superior therapeutic efficacy of this regimen in Asians.

KW - Chronic hepatitis C

KW - Korean

KW - Pegylated interferon alpha

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=84862910095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862910095&partnerID=8YFLogxK

U2 - 10.5009/gnl.2012.6.1.98

DO - 10.5009/gnl.2012.6.1.98

M3 - Article

VL - 6

SP - 98

EP - 106

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 1

ER -